Becton Dickinson (BD) medical device company will pay $175 million for “repeatedly” misleading investors about its Alaris infusion pump, a product the company knew was flawed and was sold without the required patient-safety approvals, the Securities and Exchange Commission (SEC) said.
Manufacturers are required to get approvals from the Food and Drug Administration (FDA) for complex medical devices like infusion pumps.
